210 related articles for article (PubMed ID: 22642738)
21. Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis.
Kumasaka R; Nakamura N; Shirato K; Fujita T; Murakami R; Shimada M; Nakamura M; Osawa H; Yamabe H; Okumura K
Clin Exp Nephrol; 2006 Sep; 10(3):222-5. PubMed ID: 17009081
[TBL] [Abstract][Full Text] [Related]
22. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
Schippling S; O'Connor P; Knappertz V; Pohl C; Bogumil T; Suarez G; Cook S; Filippi M; Hartung HP; Comi G; Jeffery DR; Kappos L; Goodin DS; Arnason B
J Neurol; 2016 Jul; 263(7):1418-26. PubMed ID: 27177997
[TBL] [Abstract][Full Text] [Related]
23. Fixed drug eruption with interferon-beta-1b.
Tai YJ; Tam M
Australas J Dermatol; 2005 Aug; 46(3):154-7. PubMed ID: 16008645
[TBL] [Abstract][Full Text] [Related]
24. [Interferon therapy of multiple sclerosis].
Jensen D
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
[TBL] [Abstract][Full Text] [Related]
25. The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients.
Varoglu AO; Varoglu E; Bayraktar R; Aygul R; Ulvi H; Yildirim K
J Back Musculoskelet Rehabil; 2010; 23(1):25-9. PubMed ID: 20231786
[TBL] [Abstract][Full Text] [Related]
26. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
[TBL] [Abstract][Full Text] [Related]
27. Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment.
Reske D; Walser A; Haupt WF; Petereit HF
Acta Neurol Scand; 2004 Jan; 109(1):66-70. PubMed ID: 14653853
[TBL] [Abstract][Full Text] [Related]
28. Factors leading patients to discontinue multiple sclerosis therapies.
Daugherty KK; Butler JS; Mattingly M; Ryan M
J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
[TBL] [Abstract][Full Text] [Related]
29. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.
Warabi Y; Matsumoto Y; Hayashi H
J Neurol Sci; 2007 Jan; 252(1):57-61. PubMed ID: 17125797
[TBL] [Abstract][Full Text] [Related]
30. [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices].
Brochet B; Lemaire G; Beddiaf A;
Rev Neurol (Paris); 2006 Jun; 162(6-7):735-40. PubMed ID: 16840982
[TBL] [Abstract][Full Text] [Related]
31. Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?
Durelli L; Oggero A; Verdun E; Isoardo G; Ricci A; Barbero P; Bergamasco B
J Neurol Sci; 2000 Sep; 178(1):37-41. PubMed ID: 11018247
[TBL] [Abstract][Full Text] [Related]
32. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
33. From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.
Prosperini L; Mancinelli CR; Pozzilli C; Grasso MG; Clemenzi A; Collorone S; Pontecorvo S; Francia A; Villani V; Koudriavtseva T; Buttari F; Centonze D; Di Battista G; Frisullo G; Galgani S; Gasperini C
Eur Neurol; 2014; 71(5-6):233-41. PubMed ID: 24480868
[TBL] [Abstract][Full Text] [Related]
34. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
[No Abstract] [Full Text] [Related]
35. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
Schwid SR; Goodman AD; Mattson DH
Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
[TBL] [Abstract][Full Text] [Related]
37. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous Side-effects of Immunomodulators in MS.
Lebrun C; Bertagna M; Cohen M
Int MS J; 2011 Sep; 17(3):88-94. PubMed ID: 21689492
[TBL] [Abstract][Full Text] [Related]
39. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
[TBL] [Abstract][Full Text] [Related]
40. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
